Polymyxin B Does NOT Require Renal Dose Adjustment
Unlike colistin, polymyxin B dosing should remain unchanged in patients with renal impairment, including those on continuous renal replacement therapy (CRRT). This is a critical pharmacokinetic distinction that directly impacts patient safety and treatment efficacy.
Key Pharmacokinetic Principle
Polymyxin B plasma concentrations are not influenced by renal function 1. The drug is dosed based on body weight, and its clearance occurs through non-renal mechanisms. This fundamentally differentiates it from colistin (polymyxin E), which requires complex renal-based dose adjustments.
Standard Dosing Regimen
Loading dose: 2-2.5 mg/kg (should be given to ALL patients regardless of renal function) 1
Maintenance dose: 1.5-3 mg/kg/day divided into 2 doses 1
- The FDA label specifies 15,000-25,000 units/kg/day for adults with normal kidney function, with reduction "downward" for renal impairment 2
- However, the 2015 ICU Task Force guidelines explicitly state the same dose applies to patients on CRRT 1
Special Populations
Patients on CRRT
No dose adjustment necessary 1. Use the standard maintenance dose of 1.5-3 mg/kg/day. The loading dose should still be administered.
Patients with Renal Insufficiency (Not on Dialysis)
The evidence here shows conflicting perspectives:
- Guideline recommendation (2015): Dosing based on body weight; plasma concentration not influenced by renal function 1
- Recent research evidence (2021-2023): Suggests renal function DOES affect polymyxin B clearance, with decreased clearance in renal insufficiency 3, 4
Clinical resolution: Given the lower incidence of renal failure with polymyxin B compared to colistin 1, and recent real-world data showing lower mortality with reduced doses in renal impairment 5, a cautious approach favoring the lower end of the dosing range (1.5 mg/kg/day maintenance) is prudent in patients with significant renal dysfunction (CrCL <30 mL/min). However, the loading dose should always be given.
Critical Safety Considerations
Nephrotoxicity Monitoring
- Polymyxin B appears less nephrotoxic than colistin 1
- Monitor renal function closely, particularly within the first 3 days 6
- Avoid concurrent nephrotoxic agents (aminoglycosides, loop diuretics) 7
Therapeutic Drug Monitoring (TDM)
While not routinely available, TDM is recommended when possible, particularly in:
- Patients with extremes of renal function 3
- Critically ill patients with fluctuating renal function 8, 9
- Patients not responding to therapy
Common Pitfalls to Avoid
Do NOT extrapolate colistin dosing principles to polymyxin B - they are pharmacokinetically distinct drugs despite being in the same class 1
Do NOT omit the loading dose in renal impairment - this is explicitly contraindicated and delays achievement of therapeutic levels 1
Do NOT use the outdated FDA label recommendation for dose reduction without considering the 2015 guideline evidence showing non-renal clearance 1, 2
Do NOT assume CRRT removes significant polymyxin B - dialysate recovery is only ~22%, insufficient to warrant dose adjustment 3
Practical Algorithm
For ALL patients:
- Give loading dose: 2-2.5 mg/kg
Then for maintenance:
- Normal renal function or CRRT: 1.5-3 mg/kg/day divided q12h
- Severe renal impairment (CrCL <30, not on dialysis): Consider lower range (1.5-2 mg/kg/day) with close monitoring
- Adjust based on clinical response and toxicity, NOT creatinine clearance formulas
The evidence strongly supports that polymyxin B is the preferred polymyxin in renal impairment precisely because it does not require the complex dose adjustments that colistin demands 1.